Company: XAIR
Filing Date: 2025-12-11
Form Type: S-1/A
Source: 0001493152-25-027294
Chunk: 9

Company: Beyond Air, Inc.
Filing Date: 2025-12-11
Form: S-1/A
Chunk 9
---
-approved NO vasodilation treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered (<100 ppm). Given that NO is produced naturally by the body as an innate immunity mechanism, at a concentration of 200 ppm, supplemental high dose NO should aid in the body’s fight against infection. Based on our preclinical studies and clinical trials, we believe that 150 ppm is the minimum therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor comparable foreign regulatory agencies in other countries or regions have approved any NO formulation and/or delivery system for >80 ppm NO.

Smaller Reporting Company

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is $250 million or more measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is $700 million or more measured on the last business day of our second fiscal quarter.

Corporate Information

We were incorporated on April 28, 2015 under Delaware law. On June 25, 2019, our name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc. Our principal executive offices are located at 900 Stewart Avenue, Suite 301, Garden City, New York 11530, and our telephone number is (516) 665-8200. Our website address is www.beyondair.net. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus.

| 2 |

<div align='center'>THE OFFERING</div>

| Issuer                     |     | Beyond                                                                                                                                 
 Air, Inc.                                                                                                                              |
| Shares                     
 of Common Stock            
 Offered                    
 by the Selling Stockholder |     | Up                                                                                                                                     
 to 1,600,000 shares of common stock that we may issue and sell to Streeterville from time to time under the Purchase Agreement         |
| Selling                    
 Stockholder                |     | Streeterville                                                                                                                          
 Capital, LLC. See “S